ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25mar497

Metabolic Rivalry and Immune Signaling in the Carcinogenic Cellular Niche: Challenges and Therapeutic Advances

Sangeedha G[1]; Madhu mitha T[2]; Bharathi B[3]*; DeepaC.Philip[4]

[1,2],MSc MLT II year, Department of Medical Laboratory Technology, MMM College of Health Sciences, Chennai
[3], Associate Professor of Microbiology, MMM College of Health Sciences, Chennai
[4], Principal, MMM College of Health Sciences, Chennai
*Corresponding Author: Bharathi B[3]

Publication Date: 2025/03/22

Abstract: Neoplastic Microenvironment is a key factor influencing cancer Proliferation, spread, and therapeutic outcomes by mediating interactions between malignant and immune cells. One of the most significant aspects of these interactions is metabolic competition, wherein cancer cells alter their Cellular metabolic mechanisms—including anaerobic glycolysis, lipid oxidation, and amino acid utilization—to gain a survival advantage over immune cells. This metabolic reprogramming results in the accumulation of immunosuppressive byproducts like lactate, which impair the role of CTLs and NK cells in orchestrating tumor-directed immune responses evasion. The metabolic heterogeneity within the TME adds another layer of complexity, as tumors develop adaptive mechanisms to withstand hypoxia and nutrient deprivation, while immune cells face metabolic stress that leads to dysfunction and exhaustion. Immunotherapies, particularly Immune-modulating drugs targeting PD-1 and CTLA-4 receptors, aim to rejuvenate T-cell responses but often face challenges due to tumor-induced metabolic suppression, featuring mitochondrial dysregulation and surplus ROS production. Addressing these metabolic constraints through targeted interventions offers promising avenues to enhance immune responses and improve cancer treatment outcomes. A deeper understanding of tumor metabolism may lead to innovative therapeutic strategies aimed at disrupting tumor-mediated immune suppression while restoring immune cell functionality.

Keywords: *Tumor Microenvironment, Cancer Metabolism, Immune Evasion, Warburg Effect, Metabolic Suppression, Immunotherapy, Immune Checkpoint Inhibitors, Metabolic Reprogramming, Reactive Oxygen Species, Nutrient Competition, Glycolysis, T-Cell Exhaustion.*

How to Cite: Sangeedha G; Madhu mitha T; Bharathi B; DeepaC.Philip (2025) Metabolic Rivalry and Immune Signaling in the Carcinogenic Cellular Niche: Challenges and Therapeutic Advances. *International Journal of Innovative Science and Research Technology*, 10(3), 608-610. https://doi.org/10.38124/ijisrt/25mar497

I. INTRODUCTION

Rather than being a passive setting, the TME actively participates in tumor development. The interplay of metabolic processes between tumor and immune cells in this setting shows a significant role in tumor growth and resistance to treatment (Antonio *et al.*, 2021). Unlike normal cells, cancer cells exhibit altered metabolic behaviors, primarily due to the Warburg effect, where aerobic glycolysis is favored over oxidative phosphorylation (Warburg & Dickens, 1930). This metabolic shift leads to nutrient depletion and the accumulation of metabolic byproducts such as lactate, creating an immunosuppressive environment that weakens immune cell functions (Lapa *et al.*, 2020). The TME consists of cellular living and structural elements that influence cancer progression, metastasis, and therapy resistance (Nabi & Le, 2021). A crucial aspect of this environment is the metabolic interplay between cancer cells and immune cells, which affects immune evasion and treatment outcomes (Guerra *et al.*, 2020). This review explores cancer cell metabolic heterogeneity, nutrient competition, immune suppression via metabolism, and the implications of these processes on immunotherapy. Understanding these dynamics can facilitate the development of novel treatment strategies targeting both tumor cells and the supportive TME.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25mar497

II. TUMOR METABOLISM AND IMMUNE SUPPRESSION

Malignant cells favor glycolysis for energy generation and macromolecule synthesis, even under aerobic conditions, a process termed the Warburg effect (Warburg & Dickens, 1930). Several oncogenic factors contribute to this metabolic shift, including:

- Oncogene-driven signaling (e.g., MYC, AKT) (Hensley *et al*., 2013)
- Downregulation of tumor-suppressive pathways (e.g., p53) (Fukuda *et al*., 2007)
- Hypoxia-induced stabilization of HIF1α (Papandreou *et al*., 2006)
- Upregulation of glycolytic enzymes (e.g., hexokinase, pyruvate kinase) (Hoang *et al*., 2019) Beyond glycolysis, tumor cells also exploit other metabolic pathways such as the glucose oxidation via the pentose phosphate pathway, fatty acid generation, and glutaminolysis to sustain rapid tumor expansion and viability (Hensley *et al*., 2013).

Nutrient Competition in Neoplastic Microenvironment within TME, tumour cells outcompete immune cells for vital nutrients, including glucose, amino acids, and lipids (Jacobs *et al*., 2008). This metabolic competition creates a resource-limited environment that deprives cytotoxic T cells and NK cells of the energy needed to function effectively (Buck *et al*., 2015). Additionally, metabolic byproducts such as lactate contribute to an acidic environment that further suppresses immune responses (Hurley *et al*., 2020).

Immune Cell Suppression Under normal conditions, the immune system can identify and eliminate malignant cells through CTLs, NK cells, and other immune components. However, tumors employ several mechanisms to evade immune destruction, such as:

- Immune checkpoint activation (e.g., PD-1, CTLA-4) (Parry *et al*., 2005)
- Expansion of Immune-modulating regulatory T cells and myeloid suppressor populations (Grover *et al*., 2021)
- Metabolic stress that impairs T-cell activity (Scharping *et al*., 2021) Oxygen deprivation (hypoxia) and nutrient depletion cause mitochondrial dysfunction and excessive ROS production in T cells, leading to immune exhaustion and diminished effector function (Siska *et al*., 2017).

III. METABOLIC HETEROGENEITY AND CANCER PROGRESSION

Metastatic Cascade and Metabolic Adaptations Metabolic heterogeneity significantly impacts metastasis (Nabi & Le, 2021). At each stage of metastasis, from local invasion to the establishment of secondary tumors, cancer cells undergo metabolic shifts that allow them to survive in circulation, evade immune responses, and colonize distant organs (Antonio *et al*., 2021).

Stromal and Immune Cell Interactions The TME is composed of multiple cell types, including:

- Immune cells: B cells, T cells, NK cells, macrophages, and neutrophils (Vesely *et al*., 2013)
- Stromal cells: Fibroblasts, adipocytes, and endothelial cells (Zandberg *et al*., 2021) Cancer-associated fibroblasts and tumor-associated macrophages actively support tumor development by releasing growth factors and promoting an immunosuppressive environment (Xu *et al*., 2021). In contrast, immune cells within the TME may either support or inhibit tumor growth, depending on the metabolic conditions they encounter (Guerra *et al*., 2020).

IV. METABOLIC IMMUNE SUPPRESSION AND IMMUNOTHERAPY

Challenges in T-Cell Activation For T-cell activation and function, several signals are required, including:

- Antigen receptor binding (Frauwirth *et al*., 2002)
- Co-stimulatory receptor signaling (Klein Geltink *et al*., 2017)
- Cytokine-mediated growth factor stimulation (Buck *et al*., 2015)
- Adequate metabolic support for proliferation (Jacobs *et al*., 2008) In the TME, metabolic suppression interferes with these critical processes, leading to immune exhaustion (Scharping *et al*., 2021). Strategies to counteract these effects include immune checkpoint blockade and metabolic reprogramming (Zandberg *et al*., 2021).

Checkpoint Blockade and Metabolic Resistance: Immune checkpoint inhibitors (e.g., anti-PD-1, anti-CTLA-4) have significantly improved cancer therapy. Nevertheless, tumors develop resistance via mechanisms such as antigen presentation impairment and metabolic inhibition of T cell responses (Parry *et al*., 2005). Addressing these metabolic challenges is essential for improving immunotherapy effectiveness (June, 2007). Potential strategies include:

- Increasing glucose availability to support T-cell metabolism (Frauwirth *et al*., 2002)
- Reducing metabolic byproducts like lactate to alleviate immune suppression (Papandreou *et al*., 2006)
- Enhancing mitochondrial function to improve T-cell persistence and function (Siska *et al*., 2017)

By targeting tumor metabolism alongside immunotherapy, researchers aim to develop more effective cancer treatments that overcome resistance mechanisms and enhance anti-tumor immunity (Kershaw *et al*., 2013).

V. CONCLUSION

The metabolic complexity of the pathological tumor setting, contributing significantly to malignancy. metastasis, and treatment response. A better understanding of these metabolic alterations provides new opportunities for therapeutic advancements. Targeting tumor metabolism while supporting immune cell function may enhance the efficacy of immunotherapy. Future research should focus on

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25mar497

metabolic reprogramming strategies to optimize patient outcomes in cancer therapy.

REFERENCES

[1]. Antonio, M. J., Zhang, C., & Le, A. (2021). Different tumor microenvironments lead to different metabolic phenotypes. *Advances in Experimental Medicine and Biology, 1311*, https://doi.org/10.1007/978-3-030-65768-0_10

[2]. Nabi, K., & Le, A. (2021). The intratumoral heterogeneity of cancer metabolism. *Advances in Experimental Medicine and Biology, 1311*, https://doi.org/10.1007/978-3-030-65768-0_11

[3]. Hoang, G., Udupa, S., & Le, A. (2019). Application of metabolomics technologies toward cancer prognosis and therapy. *International Review of Cell and Molecular Biology, 347*, 191–223.

[4]. Lapa, B., Goncalves, A. C., Jorge, J., Alves, R., Pires, A. S., Abrantes, A. M., *et al*. (2020). Acute myeloid leukemia sensitivity to metabolic inhibitors: Glycolysis showed to be a better therapeutic target. *Medical Oncology, 37(8)*, 72.

[5]. Hurley, H. J., Dewald, H., Rothkopf, Z. S., Singh, S., Jenkins, F., Deb, P., *et al*. (2020). AMPK regulates metabolic reprogramming necessary for interferon production in human plasmacytoid dendritic cells. *Journal of Leukocyte Biology*.

[6]. Guerra, L., Bonetti, L., & Brenner, D. (2020). Metabolic modulation of immunity: A new concept in cancer immunotherapy. *Cell Reports, 32(1)*, 107848.

[7]. Vesely, S., *et al*. (2013). Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome. *World Journal of Urology, 31(2)*, 299–304.

[8]. Klein Geltink, R. I., O'Sullivan, D., Corrado, M., Bremser, A., Buck, M. D., Buescher, J. M., *et al*. (2017). Mitochondrial priming by CD28. *Cell, 171*, 385–397.e11. https://doi.org/10.1016/j.cell.2017.08.018

[9]. Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., *et al*. (2005). CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. *Molecular and Cellular Biology, 25*, 9543–9553. https://doi.org/10.1128/MCB.25.21.9543-9553.2005

[10]. Frauwirth, K. A., Riley, J. L., Harris, M. H., Parry, R. V., Rathmell, J. C., Plas, D. R., *et al*. (2002). The CD28 signaling pathway regulates glucose metabolism. *Immunity, 16*, 769–777. https://doi.org/10.1016/s1074-7613(02)00323-0

[11]. Jacobs, S. R., Herman, C. E., Maciver, N. J., Wofford, J. A., Wieman, H. L., Hammen, J. J., & Rathmell, J. C. (2008). Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. *Journal of Immunology, 180(7)*, 4476–4486. https://doi.org/10.4049/jimmunol.180.7.4476

[12]. Siska, P. J., Beckermann, K. E., Mason, F. M., Andrejeva, G., Greenplate, A. R., Sendor, A. B., *et al*. (2017). Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. *JCI Insight, 2*, e93411. https://doi.org/10.1172/jci.insight.93411

[13]. Zandberg, D. P., Menk, A. V., Velez, M., Normolle, D., DePeaux, K., Liu, A., *et al*. (2021). Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck. *Journal for Immunotherapy of Cancer, 9*, e002088. https://doi.org/10.1136/jitc-2020-002088

[14]. Xu, S., Chaudhary, O., Rodríguez-Morales, P., Sun, X., Chen, D., Zappasodi, R., *et al*. (2021). Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8(+) T cells in tumors. *Immunity, 54*, 1561–1577.e7. https://doi.org/10.1016/j.immuni.2021.05.003

[15]. Warburg, O. H., & Dickens, F. (1930). *The metabolism of tumours*. Constable.

[16]. Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006). HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. *Cell Metabolism, 3*, 187–197. https://doi.org/10.1016/j.cmet.2006.01.012

[17]. Fukuda, R., Zhang, H., Kim, J. W., Shimoda, L., Dang, C. V., & Semenza, G. L. (2007). HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. *Cell, 129*, 111–122. https://doi.org/10.1016/j.cell.2007.01.047

[18]. Hensley, C. T., Wasti, A. T., & DeBerardinis, R. J. (2013). Glutamine and cancer: Cell biology, physiology, and clinical opportunities. *Journal of Clinical Investigation, 123*, 3678–3684. https://doi.org/10.1172/JCI69600

[19]. Buck, M. D., O'Sullivan, D., & Pearce, E. L. (2015). T cell metabolism drives immunity. *Journal of Experimental Medicine, 212*, 1345–1360. https://doi.org/10.1084/jem.20151159

[20]. Grover, A., Sanseviero, E., Timosenko, E., & Gabrilovich, D. I. (2021). Myeloid-derived suppressor cells: A propitious road to clinic. *Cancer Discovery, 11*, 2693–2706. https://doi.org/10.1158/2159-8290.CD-21-0764

[21]. Munn, D. H., *et al*. (2002). Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. *Science, 297(5588)*, 1867–1870.

[22]. June, C. H. (2007). Adoptive T cell therapy for cancer in the clinic. *The Journal of Clinical Investigation, 117(6)*, 1466–1476.

[23]. Kershaw, M. H., Westwood, J. A., & Darcy, P. K. (2013). Gene-engineered T cells for cancer therapy. *Nature Reviews Cancer, 13(8)*, 525–541.

[24]. Scharping, N. E., Menk, A. V., Rivadeneira, D. B., Ford, B. R., Rittenhouse, N. L., Peralta, R., *et al*. (2021). Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. *Nature Immunology, 22*, 205–215. https://doi.org/10.1038/s41590-020-00834-9